Advertisement

Topics

STAT Plus: Intercept stock rides a roller coaster after FDA note on Ocaliva

14:31 EDT 22 Sep 2017 | STAT

Intercept stock fell further after the FDA said the company’s lead drug, Ocaliva, increased the risk of liver injury and death in some patients.

Original Article: STAT Plus: Intercept stock rides a roller coaster after FDA note on Ocaliva

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Intercept stock rides a roller coaster after FDA note on Ocaliva"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...